The complement system in central nervous system diseases

Immunologic Research

Volumn 24, Issue 1, 2001, Pages 79-86

  Rus, H ^a   Niculescu, F ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Astrocytes; Cell Cycle; Oligodendrocytes; Terminal Complement Complexes

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; COMPLEMENT COMPONENT C5B; MYELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; INFLAMMATION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT C5; COMPLEMENT C5B; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; MYELIN SHEATH; OLIGODENDROGLIA; RATS;

EID: 0034957431     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:24:1:79     Document Type: Article

References (53)

1. Studies on the complement system i n cerebrospinal fluid
2. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation
3. Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus
4. Biosynthesis and regulation of complement by cells of thecentral nervous system
5. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines
6. Transforming growth factor-beta 1 inhibits inflammatory cytokine induced C3 gene expression in astrocytes
7. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain
8. Neurons express proteins of the classical complement pathway in Alzheimer disease
9. Expression of a complete and functional complement system by human neuronal cells in vitro
10. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis
11. Complement regulatory protein expression by a human oligodendrocyte cell line: Cytokine regulation and comparison with astrocytes
12. The expression of complement regulatory proteins by adult human oligodendrocytes
13. Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis
14. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury
15. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions
16. Multiple sclerosis: Remyelination of nascent lesions
17. Multiple sclerosis: Remyelination in acute lesions
18. Complement system and liquor cerebrospinalis. 3. The behavior of complete C′ and C′1-C′4 in serum and liquor of patients with multiple sclerosis
19. Complement factors in multiple sclerosis
20. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis
21. Cerebrospinal fluid C9 in demyelinating disease
22. Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases
23. Immunocytochemical localization of the terminal complement complex in multiple sclerosis
24. Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies
25. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies
26. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody
27. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59
28. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system
29. Complement regulatory molecules on human myelin and glial cells: Differential expression affects the deposition of activated complement proteins
30. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement
31. Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes
32. Sublytic complement attack induces cell cycle in oligodendrocytes
33. Proliferation of mature oligodendrocytes after trauma to the central nervous system
34. Can oligodendrocytes attached to myelin proliferate?
35. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes
36. Multiple extracellular signals are required for long-term oligodendrocyte survival
37. Programmed cell death and the control of cell survival: Lessons from the nervous system
38. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation
39. Enhanced oligodendrocyte survival by C5b-9 through inhibition of mitochondrial pathway of apoptosis
40. Immunohistochemical localization of C5b-9, S-protein, C3d, and apolipoprotein B in human arterial tissues with atherosclerosis
41. Complement activation in the central nervous system following blood-brain barrier damage in man
42. The membrane attack complex and the bystander effect in cerebral vasospasm
43. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein
44. Rapid ischemic cell death in immature oligodendrocytes: A fatal glutamate release feedback loop
45. Normal and abnormal biology of the beta-amyloid precursor protein
46. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study
47. Complement activation by beta-amyloid in Alzheimer disease
48. Compement-dependent proinflammatory properties of the Alzheimer's disease β-peptide
49. Mechanisms of cell death in Alzheimer disease-immunopathology
50. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease
51. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue
52. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins
53. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease